Cardiology
From the Journals
Poor response to statins hikes risk of cardiovascular events
Patients with better outcomes were more likely to have initiated therapy with a more potent drug.
From the Journals
Canagliflozin lowers kidney failure risk in T2D: CREDENCE
The SGLT2 inhibitor also cut cardiovascular events.
Conference Coverage
PIONEER-HF Extension: Don’t stall starting sacubitril/valsartan
NEW ORLEANS – “The early improvement in postdischarge outcomes supports the in-hospital initiation of sacubitril/valsartan.” – Dr. Adam D. DeVore...
News
Low LDL cholesterol may increase women’s risk of hemorrhagic stroke
Investigators found no association between HDL cholesterol and risk of hemorrhagic stroke or between total cholesterol and risk of hemorrhagic...
From the Journals
New data further suggest that stress does a number on the CV system
Conference Coverage
Dapagliflozin’s cardiovascular benefits bloom in T2D with prior MI
NEW ORLEANS – New clinically important insights from DECLARE-TIMI 58 trial.
Conference Coverage
Alirocumab reduces both type 1 and 2 MIs
NEW ORLEANS – The ODYSSEY Outcomes trial provides first-ever evidence that lowering LDL prevents type 2 MI.
From the Journals
CV disease and mortality risk higher with younger age of type 2 diabetes diagnosis
In contrast, developing type 2 diabetes over the age of 80 years had little impact on risk.
News
FDA names 40 ARBs that are free of nitrosamines
The risk of discontinuation outweighs the risk of continuation of ARBs.
Conference Coverage
Despite failed primary endpoint, MI alert device has predictive value
WASHINGTON – An extended analysis of a device to detect myocardial infarction suggests utility in high-risk patients.
Clinical Inquiries
What are the risks of long-term PPI use for GERD symptoms in patients > 65 years?
EVIDENCE-BASED ANSWER: The use of proton pump inhibitors (PPIs) to control gastroesophageal reflux disease (GERD) is significantly associated with...